Compare Cadila Healthcare with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs FRESENIUS KABI ONCO. - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE FRESENIUS KABI ONCO. CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 28.5 22.1 128.6% View Chart
P/BV x 5.0 3.1 160.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CADILA HEALTHCARE   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
FRESENIUS KABI ONCO.
Mar-13
CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs352176 200.2%   
Low Rs20779 263.1%   
Sales per share (Unadj.) Rs139.237.7 369.4%  
Earnings per share (Unadj.) Rs11.85.1 231.0%  
Cash flow per share (Unadj.) Rs18.66.7 276.2%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs101.442.5 238.2%  
Shares outstanding (eoy) m1,023.74158.23 647.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.03.4 59.4%   
Avg P/E ratio x23.725.0 95.1%  
P/CF ratio (eoy) x15.018.9 79.5%  
Price / Book Value ratio x2.83.0 92.2%  
Dividend payout %29.80-   
Avg Mkt Cap Rs m286,03320,135 1,420.6%   
No. of employees `00013.41.2 1,163.6%   
Total wages/salary Rs m24,145703 3,433.6%   
Avg. sales/employee Rs Th10,632.75,176.2 205.4%   
Avg. wages/employee Rs Th1,801.2610.4 295.1%   
Avg. net profit/employee Rs Th898.5699.6 128.4%   
INCOME DATA
Net Sales Rs m142,5315,963 2,390.3%  
Other income Rs m1,13918 6,327.8%   
Total revenues Rs m143,6705,981 2,402.1%   
Gross profit Rs m24,1981,430 1,692.0%  
Depreciation Rs m6,965258 2,700.7%   
Interest Rs m3,418-26 -13,146.2%   
Profit before tax Rs m14,9541,216 1,229.6%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m3,198342 934.5%   
Profit after tax Rs m12,044806 1,494.5%  
Gross profit margin %17.024.0 70.8%  
Effective tax rate %21.428.1 76.0%   
Net profit margin %8.513.5 62.5%  
BALANCE SHEET DATA
Current assets Rs m87,1545,102 1,708.4%   
Current liabilities Rs m82,6942,385 3,466.7%   
Net working cap to sales %3.145.6 6.9%  
Current ratio x1.12.1 49.3%  
Inventory Days Days71150 47.6%  
Debtors Days Days94113 82.8%  
Net fixed assets Rs m133,2365,148 2,588.1%   
Share capital Rs m1,024158 647.3%   
"Free" reserves Rs m102,7336,556 1,567.1%   
Net worth Rs m103,7576,732 1,541.3%   
Long term debt Rs m32,146952 3,376.0%   
Total assets Rs m236,86610,388 2,280.2%  
Interest coverage x5.4-45.8 -11.7%   
Debt to equity ratio x0.30.1 219.0%  
Sales to assets ratio x0.60.6 104.8%   
Return on assets %6.57.5 86.9%  
Return on equity %11.612.0 97.0%  
Return on capital %13.714.6 94.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m52,7525,298 995.8%   
Fx outflow Rs m14,5041,772 818.4%   
Net fx Rs m38,2483,525 1,084.9%   
CASH FLOW
From Operations Rs m25,0541,274 1,966.4%  
From Investments Rs m-10,123-1,204 840.6%  
From Financial Activity Rs m-10,942-196 5,579.8%  
Net Cashflow Rs m3,989-126 -3,158.4%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 9.6 61.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 42,599 103.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DIVIS LABORATORIES  GLENMARK PHARMA  SUN PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Apr 15, 2021 03:37 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS